{"id":"W2558450726","doi":"10.1093/neuonc/now212.048","title":"ACTR-50. MARIZOMIB (MRZ) WITH BEVACIZUMAB (BEV) IN WHO GRADE IV MALIGNANT GLIOMA (G4 MG): FULL ENROLLMENT RESULTS FROM THE PHASE 1, MULTICENTER, OPEN-LABEL STUDY","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Glioma; Internal medicine; Population; Progressive disease; Cohort; Surgery; Tolerability; Gastroenterology; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006989224,0.0008285255,0.0009423008,0.0003569461,0.0002284254,0.0006204702,0.0005700271,0.0007052704,0.002760257],"category_scores_gemma":[0.0003969665,0.0004271401,0.0008083762,0.0002837332,0.0004199294,0.0005468271,0.000191353,0.001565311,0.0009475184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008096158,"about_ca_system_score_gemma":0.0009530576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002173573,"about_ca_topic_score_gemma":0.006111093,"domain_scores_codex":[0.9997508,0.0001020141,0.00001423253,0.00003423147,0.00003358481,0.00006513361],"domain_scores_gemma":[0.9998154,0.00002101254,0.00004158924,0.0000154155,0.00001186517,0.00009470168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5253708,0.06675051,0.01047737,0.001168554,0.001761497,0.0005640585,0.0004327027,0.003458583,0.1348362,0.0005074086,0.0143161,0.2403562],"study_design_scores_gemma":[0.3019839,0.6188098,0.04535358,0.00008711498,0.001034157,0.0007044604,0.0001119888,0.002245381,0.01738543,0.0003078599,0.01193072,0.00004553262],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9929007,0.002489686,0.0003244004,0.000315765,0.00007749711,0.0006929137,0.0007658041,0.0001522826,0.002280885],"genre_scores_gemma":[0.9914986,0.002337512,0.0006301287,0.0004469364,0.00008883633,0.0005023857,0.001828075,0.00003097924,0.00263645],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002760257,"threshold_uncertainty_score":0.009234011,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05990842500613037,"score_gpt":0.3412815241594815,"score_spread":0.2813730991533511,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}